Answer
The press release you referenced reports the results of the two pivotal Phase 3 trials (ATTAIN‑1 and ATTAIN‑2) for Lilly’s once‑daily oral GLP‑1 drug, orforglipron. It highlights the efficacy (average weight loss of up to 27.3 lb) and a safety/tolerability profile that mirrors injectable GLP‑1 agents, but it does not include any specific information about the company’s projected timeline for:
- U.S. FDA approval (e.g., expected filing date, anticipated review period, or target approval month/year), or
- Commercial launch (e.g., planned launch date, market‑entry strategy, or rollout schedule after approval).
Therefore, based solely on the news excerpt you provided, there is no disclosed timeline for either FDA approval or the subsequent commercial launch of orforglipron. If you need that timeline, you would have to look for additional statements from Eli Lilly—such as a separate investor‑relations update, a SEC filing, or a follow‑up press release—that specifically addresses regulatory and launch plans.